China: Anpac Bio-Medical to float on Nasdaq

Chief executive Chris Yu inspects Anpac Bio's proprietary cancer differentiation analysis liquid biopsy technology

Cancer-screening diagnostics company Anpac Bio-Medical plans to raise up to US$27m in an initial public offering on Nasdaq. The Lishui-based company is selling 1.7 million American Depository Shares at a price range of US$12 to US$14. This would give the company a market capitalisation of US$150m at the midpoint. Founded in 2010, Anpac markets and…

You must be a HMI Subscriber to view this content.

Subscribe Now »